292 related articles for article (PubMed ID: 27310200)
1. Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.
Emoto C; Vinks AA; Fukuda T
Ther Drug Monit; 2016 Oct; 38(5):607-13. PubMed ID: 27310200
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
Amundsen R; Åsberg A; Ohm IK; Christensen H
Drug Metab Dispos; 2012 Apr; 40(4):655-61. PubMed ID: 22205779
[TBL] [Abstract][Full Text] [Related]
3. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.
Wu FL; Tsai MK; Chen RR; Sun SW; Huang JD; Hu RH; Chen KH; Lee PH
Pharmacotherapy; 2005 May; 25(5):646-53. PubMed ID: 15899725
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
[TBL] [Abstract][Full Text] [Related]
7. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
[TBL] [Abstract][Full Text] [Related]
10. Acute drug toxicity related to drinking herbal tea in a kidney transplant recipient.
Kwan LP; Mok MM; Ma MK; Lam MF
Ren Fail; 2014 Mar; 36(2):309-12. PubMed ID: 24180243
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.
Lamoureux F; Picard N; Boussera B; Sauvage FL; Marquet P
Fundam Clin Pharmacol; 2012 Aug; 26(4):463-72. PubMed ID: 21631587
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Rostaing L; Christiaans MH; Kovarik JM; Pascual J
Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.
Renders L; Frisman M; Ufer M; Mosyagin I; Haenisch S; Ott U; Caliebe A; Dechant M; Braun F; Kunzendorf U; Cascorbi I
Clin Pharmacol Ther; 2007 Feb; 81(2):228-34. PubMed ID: 17192769
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
Schachter AD; Benfield MR; Wyatt RJ; Grimm PC; Fennell RS; Herrin JT; Lirenman DS; McDonald RA; Munoz-Arizpe R; Harmon WE
Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus pharmacokinetic differences between children and adults.
Venkataramanan R; Sindhi R
Pediatr Transplant; 2006 Dec; 10(8):872-4. PubMed ID: 17096752
[No Abstract] [Full Text] [Related]
16. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.
Vanhove T; Annaert P; Kuypers DR
Drug Metab Rev; 2016; 48(1):88-112. PubMed ID: 26912097
[TBL] [Abstract][Full Text] [Related]
17. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
18. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
20. Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.
Kloster-Jensen K; Vethe NT; Bremer S; Abadpour S; Korsgren O; Foss A; Bergan S; Scholz H
Transpl Int; 2015 Oct; 28(10):1152-61. PubMed ID: 26046470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
